IRTC
HealthcareiRhythm Technologies, Inc. · Medical - Devices · $4B
What is iRhythm Technologies, Inc.?
iRhythm Technologies is a San Francisco-based digital healthcare company focused on cardiac monitoring. It helps physicians detect arrhythmias using wearable biosensor patches combined with cloud-based analytics.
iRhythm generates revenue through its Zio service — a patch-based ambulatory cardiac monitoring solution. Patients wear a wire-free biosensor that continuously records ECG data, which is then analyzed via a cloud platform and reported back to clinicians. The company operates primarily in the United States and has a development collaboration with Verily Life Sciences for next-generation atrial fibrillation products.
iRhythm was incorporated in 2006 and is headquartered in San Francisco, California.
- Zio XT wearable cardiac monitor
- Zio AT ambulatory ECG patch
- Cloud-based ECG data analytics platform
- Atrial fibrillation screening collaboration with Verily Life Sciences
Is IRTC a Good Stock to Buy?
UQS Score rates IRTC as Below Average overall.
Growth stands out as the clearest bright spot in IRTC's profile, reflecting meaningful expansion in its cardiac monitoring business. Risk is rated Neutral, suggesting the company does not carry outsized near-term balance sheet or operational hazards relative to peers.
Quality and Moat are both rated Weak, pointing to limited competitive durability and profitability challenges. Valuation is rated Elevated, meaning the current price already reflects considerable optimism.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does IRTC pay dividends?
No — iRhythm Technologies, Inc. does not currently pay a dividend.
iRhythm does not currently pay a dividend. As a growth-oriented digital health company, it reinvests available capital into expanding its Zio platform, broadening clinical adoption, and funding product development rather than returning cash to shareholders.
When does IRTC report earnings?
iRhythm Technologies reports earnings on a quarterly cadence, typical for US-listed equities.
The company's Growth pillar is rated Strong, suggesting its top-line trajectory has been meaningful. However, Quality and Moat ratings indicate that converting revenue growth into durable profitability remains a work in progress.
For the most recent quarter's results, visit iRhythm Technologies' investor relations page directly.
IRTC Price History
+133.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in iRhythm Technologies, Inc.?
Based on iRhythm Technologies, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does iRhythm Technologies do?
iRhythm provides wearable cardiac monitoring patches and cloud-based analytics under its Zio brand. Physicians use the service to monitor patients at risk for arrhythmias, including atrial fibrillation, without requiring wired or bulky equipment.
Does IRTC pay dividends?
No, iRhythm does not pay a dividend. The company is in a growth phase and prioritizes reinvesting capital into its Zio platform and clinical expansion over returning cash to shareholders.
When does IRTC report earnings?
iRhythm reports on a standard quarterly schedule. For exact upcoming dates, check the investor relations section of iRhythm's official website, as our data source does not cover specific earnings dates.
Is IRTC a good stock to buy?
UQS Score rates IRTC as Below Average overall. Growth is rated Strong, but Quality and Moat are both Weak, and Valuation is Elevated. Investors should weigh the growth trajectory against profitability and competitive durability concerns before deciding.
Is IRTC overvalued?
The UQS Valuation pillar for IRTC is rated Elevated, suggesting the market is pricing in significant future growth. Whether that premium is justified depends on how well the company converts its revenue expansion into sustainable earnings over time.
What is IRTC's market cap bracket?
iRhythm Technologies is classified as a mid-cap company, placing it between smaller emerging medical device firms and the large established players in the cardiac monitoring and digital health space.
Is IRTC a long-term quality investment?
From a long-term quality standpoint, IRTC's UQS profile shows a mixed picture. Strong Growth is encouraging, but Weak Quality and Moat ratings suggest the business has not yet built the durable competitive advantages typically associated with high long-term quality scores.
What sector does IRTC belong to?
iRhythm Technologies operates in the Healthcare sector, specifically within digital health and medical devices. It focuses on ambulatory cardiac monitoring — a niche that sits at the intersection of wearable technology and clinical diagnostics.
Unlock Full IRTC Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare IRTC against cardiac monitoring and digital health peers
- ✓Get the full analyst-style quality view available to Pro members
Pro Analysis
IRTC — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Aug 15, 2026 | 15.0 | 3.7 | 34.0 | 0.0 | 36.9 | 0.0 | -23.8 |
| Jul 31, 2026 | 38.8 | 17.7 | 34.0 | 91.7 | 23.5 | 26.9 | -0.2 |
| Jul 26, 2026 | 39.0 | 17.8 | 34.0 | 91.7 | 23.5 | 27.7 | +0.1 |
| Jul 25, 2026 | 38.9 | 17.8 | 34.0 | 91.7 | 23.5 | 27.5 | -0.1 |
| Jul 24, 2026 | 39.0 | 17.8 | 34.0 | 91.7 | 23.5 | 27.7 | 0.0 |
| Jul 23, 2026 | 39.0 | 17.8 | 34.0 | 91.7 | 23.5 | 27.8 | +0.1 |
| Jul 22, 2026 | 38.9 | 17.8 | 34.0 | 91.7 | 23.5 | 27.5 | 0.0 |
| Jul 18, 2026 | 38.9 | 17.7 | 34.0 | 91.7 | 23.5 | 27.4 | 0.0 |
| Jul 16, 2026 | 38.9 | 17.7 | 34.0 | 91.7 | 23.5 | 27.2 | 0.0 |
| Jul 15, 2026 | 38.9 | 17.7 | 34.0 | 91.7 | 23.5 | 27.3 | +0.1 |
IRTC — Pillar Breakdown
Quality
— 3.7/100 (25%)iRhythm Technologies, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)iRhythm Technologies, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)iRhythm Technologies, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)iRhythm Technologies, Inc. appears expensively valued relative to its fundamentals and growth prospects.
How many years of FCF the market cap represents.
Moat
— 34/100 (25%)iRhythm Technologies, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for IRTC.
Score Composition
Financial Data
More Stock Analysis
How is the IRTC UQS Score Calculated?
The UQS (Unified Quality Score) for iRhythm Technologies, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses iRhythm Technologies, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether iRhythm Technologies, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.